Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy, despite rising costs and pricing pressure forcing the company to narrow its full-year guidance. Novo Nordisk financial results The drugmaker reported a 15% increase in U.S. sales at Constant Exchange Rates (CER) in the first nine months of 2025, with operating profit increasing 10% to Danish Kroner (DKK) 95.9 billion ($14.7 billion). If one-time restructuring charges of approximately DK ...